The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population

Am J Hematol. 2010 Jul;85(7):525-8. doi: 10.1002/ajh.21722.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzamides
  • Drug Monitoring / methods*
  • Drug Monitoring / standards
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Leukocyte Count
  • Leukocytes / cytology*
  • Leukocytes, Mononuclear
  • Neutrophils
  • Organic Cation Transporter 1 / genetics*
  • Piperazines / pharmacokinetics
  • Piperazines / therapeutic use*
  • Pyrimidines / pharmacokinetics
  • Pyrimidines / therapeutic use*
  • RNA, Messenger / analysis*
  • RNA, Neoplasm / analysis

Substances

  • Benzamides
  • Organic Cation Transporter 1
  • Piperazines
  • Pyrimidines
  • RNA, Messenger
  • RNA, Neoplasm
  • Imatinib Mesylate